Research Article

Understanding the Activation of Platelets in Diabetes and Its Modulation by Allyl Methyl Sulfide, an Active Metabolite of Garlic

Navya Malladi1, Ebin Johny2, Shravan K. Upuluapu1, Vikas Tiwari1, Md Jahangir Alam1, Ramu Adela2, and Sanjay K. Banerjee1

1Department of Biotechnology, National Institute of Pharmaceutical Education and Research, Guwahati, 781101 Assam, India
2Department of Pharmacy Practice, National Institute of Pharmaceutical Education and Research, Guwahati, 781101 Assam, India

Correspondence should be addressed to Sanjay K. Banerjee; sanjay@niperguwahati.in

Received 5 August 2021; Accepted 22 September 2021; Published 19 October 2021

Academic Editor: Andrea Scaramuzza

Copyright © 2021 Navya Malladi et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Background. Diabetes mellitus (DM) is a chronic metabolic disorder associated with higher risk of having cardiovascular disease. Platelets play a promising role in the pathogenesis of cardiovascular complications in diabetes. Since last several decades, garlic and its bioactive components are extensively studied in diabetes and its complications. Our aim was to explore the antiplatelet property of allyl methyl sulfide (AMS) focusing on ameliorating platelet activation in diabetes.

Method. We used streptozotocin- (STZ-) induced diabetic rats as model for type 1 diabetes. We have evaluated the effect of allyl methyl sulfide on platelet activation by administrating AMS to diabetic rats for 10 weeks. Flow cytometry-based analysis was used to evaluate the platelet activation, platelet aggregation, platelet macrophage interaction, and endogenous ROS generation in the platelets obtained from control, diabetes, and AMS- and aspirin-treated diabetic rats.

Results. AMS treatment for 10 weeks effectively reduced the blood glucose levels in diabetic rats. Three weeks of AMS (50 mg/kg/day) treatment did not reduce the activation of platelets but a significant (p < 0.05) decrease was observed after 10 weeks of treatment. Oral administration of AMS significantly (p < 0.05) reduced the baseline and also reduced ADP-induced aggregation of platelets after 3 and 10 weeks of treatment. Furthermore, 10 weeks of AMS treatment in diabetic rats attenuated the endogenous ROS content (p < 0.05) of platelets and platelet macrophage interactions. The inhibition of platelet activation in diabetic rats after AMS treatment was comparable with aspirin treatment (30 mg/kg/day). Conclusion. We observed an inhibitory effect of allyl methyl sulfide on platelet aggregation, platelet activation, platelet macrophage interaction, and increased ROS levels in type 1 diabetes. Our data suggests that AMS can be useful to control cardiovascular complication in diabetes via inhibition of platelet activation.

1. Introduction

Diabetes mellitus (DM) is one of the chronic and complex disorders among all metabolic diseases. “Diabetes mellitus” is characterized by persistent hyperglycemia with disturbances of carbohydrate, fat, and protein metabolism resulting from defects in insulin secretion, insulin action, or both. Changes in lifestyle and rapid urbanization have increased the incidence of diabetes and its prevalence day by day. According to the International Diabetes Federation (IDF), 463 million adults (20–79-year age) are diabetic in the year 2019 with a record of 4.2 million deaths. Further, IDF interprets that there could be still more diabetic patients by the years 2030 and 2045 with an estimation of 578.4 and 700.2 million cases, respectively [1].

Type 1 diabetes is a condition that resulted from insufficient production of insulin by the pancreas while type 2 is due to improper utilization of produced insulin and ultimately leads to higher glucose levels in the circulatory system [2]. Both type 1 and type 2 diabetes require careful monitoring and control of blood glucose levels, if not this uncontrolled condition over time may root to several complications including cardiovascular disease (CVD). Cardiovascular complications in diabetes occurring as the disease progresses and leads to premature mortality [3–5]. IDF has suggested that diabetic patients are having 2-3 times more
probability of getting CVDs than nondiabetic patients [6]. The central mechanism for these cardiovascular complications in diabetes includes an imbalance in the systems which maintain the homeostasis of blood coagulation and fibrinolysis [7]. This imbalance results in diabetic thrombocytopenia [8], a condition that majorly affects platelet function and ultimately results in heart attacks or stroke in diabetes [9–12]. Scientific research has shown that antiplatelet therapy can reduce cardiovascular complications in diabetes and premature death [13, 14].

Despite having many drugs and therapies for the management of diabetes, it is still under the category of life-threatening diseases because of its complications. Reducing these cardiovascular complications in diabetes has become more challenging than controlling the disease itself. This has made an immense impact on scientific researchers for exploring new strategies for diabetic treatment. Dietary therapy in diabetes is one among them showing a tremendous effect on preventing as well as controlling diabetes [15, 16].

Among large numbers of nutritional diets, garlic has been showing a very promising effect on diabetic as well as diabetic complications [17–21]. An antiplatelet property has been observed in raw garlic, preventing cardiovascular complications in diabetes [22–24]. Scientific literature strongly supports that garlic is showing these beneficial effects mainly due to its sulfur-containing compounds [25–27]. Allyl methyl sulfide (AMS), an active metabolite observed inside the body after oral administration of raw garlic, has been shown to effect diabetes by reducing glucose levels, increasing insulin levels, and reducing hepatic oxidative stress caused by glucotoxicity in diabetes [28, 29]. However, the effect of AMS on diabetic complications in thrombosis especially on platelet activation and aggregation is yet to be reported.

Therefore, in this present study, we aim to understand the various altered parameters of platelets isolated from diabetic rats and the effect of garlic metabolite, allyl methyl sulfide, on altered parameters of diabetic platelet.

2. Materials and Methods

2.1. Reagents. Allyl methyl sulfide (cat. no. A34201-25G) and phorbol 12-myristate 13-acetate (PMA) (cat. no. P8139-1MG) were obtained from Sigma (St. Louis, Missouri, USA). Flow cytometry antibodies such as CD61 FITC antibody (cat. no. 104305) and APC anti-mouse/rat CD62P (P-selectin) antibody (cat. no. 148303) are from Bio Legend (San Diego, California, USA), and CD14 PE antibody (cat.no. 561707) is from BD Bioscience (Franklin Lakes, NJ, USA). Adenosine diphosphate (ADP) was obtained from Hi-Media (cat no. RM437-1G). H2DCFDA dye (cat no. C6827) was from Invitrogen. Cell culture reagents such as RPMI-1640 (cat no. 31800-014), antibiotic-antimycotic (100X) (cat no. 15240062), and fetal bovine serum (cat no.10270106) are from Gibco.

2.2. Animals and Study Design. Wistar rats 200-250 g were used to develop diabetes and evaluate the effect of AMS on altered platelet function in diabetes. Animals were procured from Jeeva Life Sciences (Hyderabad, India). The study was approved by the Institutional Animal Ethics Committee (IAEC) of National Institute of Pharmaceutical Education and Research (NIPER), Guwahati, India (NIPER/BT/2020/37). The animals were housed in individually ventilated cages (IVC) at an animal house facility of NIPER, Guwahati, under standard conditions (temperature 23 ± 1 °C, 50 ± 15% relative humidity, and 12 h light/dark cycle). Wistar rats were allowed free access to food and water ad libitum during the study. Post seven days of acclimatization, animals were randomly allocated into four groups (n = 6): group 1: control; group 2: diabetes (STZ 35 mg/kg); group 3: diabetes+AMS (50 mg/kg); and group 4: diabetes-aspirin (30 mg/kg). All these rats were maintained for 10 weeks. Every week, the body weight of all animals was recorded to understand the body weight gain or loss during the experimental period and glucose levels were monitored by using a glucometer (Accu Chek Active, Roche). The doses of AMS and aspirin were chosen from our previous work and scientific literature [30, 31].

2.3. Induction of Diabetes. Diabetes was chemically induced in Wistar rats (weight 200-250 g) with streptozotocin. After 6 hours of fasting, adult Wistar rats were administered with a single intraperitoneal (I.P) injection of a freshly prepared solution of streptozotocin (STZ) in ice-cold citrate buffer (0.01 M, pH 4.5) at a dose of 35 mg/kg body weight. Animals were then monitored for the next seven days for their blood glucose levels by using a glucometer (Accu Chek Active, Roche). The induction of diabetes was confirmed by monitoring fasting blood glucose. The rats with >250 mg/dl of blood glucose levels were considered diabetic.

2.4. Oral Dosing. Allyl methyl sulfide was administered orally at a dose of 50 mg/kg in corn seed oil for 10 weeks in diabetes Wister rats and referred to as the ‘diabetes +AMS’ group. Aspirin was given at a dose of 30 mg/kg in 0.5% carboxy methyl cellulose (CMC) orally to another group of diabetes Wistar rats and referred to as the ‘diabetes-aspirin’ group. The control group was referred to the rats fed with corn seed oil.

2.5. Cell Culture. Human macrophages (THP-1 cells; an acute monocyct leukemia cell line) were a kind gift from Translational Health Science and Technology Institute (THSTI, Faridabad, India). The cells were cultured in the RPMI 1640 medium enriched with fetal bovine serum (10% v/v) and antimicrobial agents (antibiotic and antymycotic) (100 U/ml) and cultured under standard conditions that are 37°C and 5% CO2 incubator (eppendorf CellXpert C170).

2.6. Blood Collection and Isolation of Platelets. The platelets were isolated from blood by dual centrifugation. It has been carried out at room temperature. Preventive measures have been taken to avoid platelet activation during the process. Initially, the animals were anesthetized with the help of isoflurane. Through retroorbital plexus using capillary tube, blood was collected into a tube containing 3.8% sodium citrate (9:1 ratio) and centrifuged at 500 rpm for 15 minutes at...
20°C temperature. The centrifugation results in isolation of platelet-rich plasma (PRP) as the upper layer in a tube. Almost 3/4th of this layer was taken into a fresh tube using a wide-bore pipette tip. Further, platelets were pelleted by centrifuging the PRP at 400 g for 10 minutes at 20°C. The platelets pellet was washed, resuspended in HEPES-Tyrode buffer.

2.7. Measuring the Number of Activated Platelets by Flow Cytometry. The in vivo activated status of isolated platelets was measured by flow cytometry using fluorochrome-tagged antibodies. All these works were carried out within 2 hours of blood collection and took all measures to avoid platelet activation during handling of the sample. 7 μl of PRP was taken in a tube and diluted by adding 50 μl of HEPES-Tyrode’s buffer having 1% BSA. Samples were added with antibody mix having FITC anti-mouse/rat CD61 antibody (platelet surface marker) and APC anti-mouse/rat CD62P antibody (platelet activation marker) diluted with HEPES-Tyrode’s buffer (with 1% BSA). Stained platelets were incubated in dark for 30 minutes at room temperature. Samples were immediately analyzed by using Attune™ NxT Flow Cytometer, where analysis was done by taking 50,000 events for each sample. The compensation was done using individual antibody-stained cells and unstained cells in order to avoid spillover from one channel to other. Platelets were gated on forward light scatter (FSC) vs. side light scatter (SSC) plot, and the percentage of CD62P positive cells is enumerated among platelets positive for CD61 cells which give % activated platelets.

2.8. Measuring Platelet Aggregation in Presence of ADP, a Platelet Agonist, by Flow cytometry. With a few modifications to previously mentioned procedure, the hypersensitivity of platelets in presence of platelet-aggregating agents (ADP) has been observed by measuring the percentage aggregation of platelets by flow cytometry [32]. 50 μl of freshly isolated platelet-rich plasma (PRP) was resuspended in 450 μl of HEPES-Tyrode buffer. Platelets were activated by adding 20 μM ADP as a final concentration and incubated for 10 minutes at 37°C under shaking conditions at 1000 rpm using a thermoshaker. Diluted PRP without agonist was used as a negative control. Cells were analyzed by flow cytometry for the presence of platelet aggregation. Platelets were differentiated from platelet aggregated by gating cells on forward light scatter (FSC) versus side light scatter (SSC) plot where the platelet aggregates are having increased size and density.

2.9. Analysis of Platelet and Macrophage Interaction by flow cytometry. The heterogeneous interactions of platelets with macrophage were analyzed by flow cytometry method using phorbol 12-myristate 13-acetate (PMA) differentiated THP-1 macrophages [33, 34].

For monocyte differentiation to macrophage, THP-1 monocytes (1.5×10⁶ cells) were seeded in 6-well plate having 1 ml of Roswell Park Memorial Institute medium (RPMI-1640) which was supplemented with 100 μg/ml streptomycin, 100 U/ml penicillin, and 10% fetal bovine serum. The monocytes were differentiated to macrophages by adding 50 ng phorbol 12-myristate 13-acetate (PMA) and incubated for 48 hours in an incubator maintaining 5% CO₂ at 37°C under humidified conditions. After 48 hours of incubation, media was changed to fresh RPMI-1640 complete media without the addition of PMA and incubated for 48 hours in an incubator.

For macrophage and platelet coculture study, isolated PRP of 7 μl was added in a culture plate having macrophages derived from THP1 and incubated for 30 minutes in a CO₂ incubator. After successive coculturing of platelets, each well has been washed with PBS to remove floating platelets. Cells were trypsinized by adding 0.25% trypsin EDTA and incubated in a CO₂ incubator for 2 minutes. The detached cells were collected in an individual tube and centrifuged at 400 g for 10 minutes at 20°C. The supernatant was discarded; the pellet was washed with PBS and fixed by incubating with 4% paraformaldehyde for 10 minutes. The cells further were washed and resuspended in PBS for labelling with fluorescently conjugated antibodies of macrophage surface marker (CD14 PE) and platelet-specific marker (CD61 FITC). The cells were incubated in dark for 30 minutes at room temperature and analyzed by Attune™ NxT Flow Cytometer. Analysis was done by gating the macrophage population under FSC vs. SSC plot. To compensate for the overlapping spectra single-stained cells were used. Finally, we measured the mean fluorescence intensity of CD61-FITC in macrophage (CD14+) population inorder to quantitate platelet macrophage interaction.

2.10. Measurement of Endogenous ROS in Platelets. Intracellular ROS was measured by using 2′,7′-dihydrodichlorofluorescein diacetate, H₂DCFDA, dye as per the procedures mentioned in articles [35, 36]. The freshly isolated PRP (7.0 μl) was diluted in 100 μl of HEPES-Tyrode’s buffer and incubated with 10 μM of H₂DCFDA dye under dark conditions for 30 min at 37°C. Later, samples were further diluted with 200 μl HEPES-Tyrode’s buffer and mixed gently with a pipette. The tubes were centrifuged at 400 g for 10 minutes at 20°C for pelleting the cells and discarding the supernatant. Further, the pellet was resuspended by adding 100 μl of HEPES-Tyrode’s buffer. The unstained samples were used as a negative control. All of these samples were analyzed using Attune™ NxT Flow Cytometer by taking 10,000 events where the mean fluorescent intensity of DCFDA in platelet population was determined for each sample.

2.11. Statistical Analysis. All the statistical analysis was performed using GraphPad Prism version 8.0.2(263) (GraphPad Software, San Diego, CA, USA), and its comparisions were made utilizing ANOVA test followed by Tukey’s test post hoc analysis. Results were expressed as mean ± standard error, and a p value < 0.05 was considered significant.

3. Results

3.1. Body Weight and Blood Glucose Level Changes in Rats. We monitored body weights and blood glucose levels of
3.2. Effect of AMS on Platelet Activation in Diabetes. The in vivo activated status of platelets in the control, diabetes, and treatment groups after 3rd and 10th weeks of study duration has been analyzed by flow cytometry. The graph represents percent CD61 positive on the X-axis and CD62P-positive platelets on the Y-axis (Figure 2(a)). The dual positive cells are considered activated platelets, and percent of the activated platelets were represented as bar graphs. At the end of 3rd week, the percentage of activated platelets was significantly increased in the diabetes group (~32.4%) when compared to the control (~19.11%). We did not observe any significant changes in the AMS and aspirin-treated groups (Figure 2(b)). Similarly, at the end of 10th week, the percentage of activated platelets was increased significantly in the diabetes group (~47.19%) when compared to the control group (~35.24%). Moreover, both aspirin and AMS treatments significantly decreased this activation of platelets (~30.15 and 25.22%, respectively) induced in diabetes (Figure 2(c)).

3.3. Effect of AMS on ADP-Induced Platelet Aggregation. To assess the effect of AMS on platelet aggregation, flow cytometry analysis was performed on platelets derived from all experiment groups in the absence or presence of ADP at the 3rd week and 10th week. Figure 3(a) represents FSC vs. SSC density plots showing the 3rd week platelet aggregation with and without ADP where aggregates are gated as R2. In the absence of ADP, we did not observe any significant change in the percentage of platelet aggregation in the diabetes group compared to the control. However, a significant decrease (3-fold) in percent aggregation was observed in the AMS- and aspirin-treated diabetes groups compared to diabetes (Figures 3(a) and 3(b)). Similarly, as shown in Figures 3(a) and 3(c), we observed a significant induction (~1.6-fold) in platelet aggregation by ADP in the diabetes group when compared to the control. With AMS and aspirin treatment, we observed a significant decrease (~3.8- and 4.2-fold, respectively) in platelet aggregation when compared to the diabetes group.

Similar flow cytometry analysis in the presence and absence of ADP was performed at the end of the 10th week, and results were represented as FSC vs. SSC density plots (Figure 4(a)). In the absence of ADP, we observed that the percentage of platelet aggregation increased 1.2-fold in diabetic rats when compared to the control (Figures 4(a) and 4(b)). A significant (p < 0.05) decrease in the percentage of platelet aggregation was observed after AMS and aspirin treatment (~2.3- and 3.3-fold, respectively) when compared to diabetes. Similarly, ADP-induced aggregation was increased by 1.1-fold in diabetes while it was decreased by 1.1- and 1.5-fold in the AMS and aspirin treatment groups, respectively (Figures 4(a) and 4(c)).

3.4. Effect of AMS on Diabetes-Induced Reactive Oxygen Species Generation in Platelets. After platelet activation and aggregation study, we measured the reactive oxygen species (ROS) levels in the platelets isolated from the control, diabetic, and treated diabetic rats at 10th week of the study duration. ROS levels in platelets were measured by using 2',7'-dichlorodihydrofluorescein diacetate (H2DCFDA) dye and analyzed it by flow cytometry. H2DCFDA dye is a direct measure of amount of ROS present in cells, and the results are expressed as the mean fluorescent intensity (MFI) of DCFDA (Figure 5). Platelet ROS levels was significantly (p < 0.05) increased in the diabetic group when compared to the control. However, the ROS levels was decreased significantly (p < 0.05) in platelets isolated from the AMS-treated diabetic rats when compared to diabetes rats. We did not observe any significant change in ROS levels in platelets isolated from the aspirin-treated diabetic rats.
3.5. Effect of AMS on Diabetes-Induced Macrophage and Platelet Interaction. Platelet macrophage interaction has been considered an important phenomenon for platelet activation in diabetes [37, 38]. To look at this interaction, macrophage and platelet were incubated together and FACS analysis was performed. THP 1, a well-known monocyte cell, were differentiated with phorbol 12-myristate 13-acetate (PMA) and later cocultured with platelets collected from the control, diabetes, and AMS-/aspirin-treated rats at 10th week of study duration. The results are shown in mean fluorescent intensity of CD61-FITC (marker of platelets) among CD14-positive THP1 macrophages. The data was represented as a bar graph (Figure 6). The increased mean fluorescent intensity was considered an aggregate cell of macrophages and platelets. In our data, the significant \( (p < 0.05) \) increase (~2.4-fold) in mean florescent intensity of CD61-FITC was observed in macrophages cocultured with diabetes platelets when compared to the control. Although we observed a decrease in macrophage platelet interactions in the AMS and aspirin treatment groups (~1.2- and 1.5-fold) when compared to the diabetic group, these changes were not significant.

4. Discussion
Diabetes mellitus is not a single clinical entity but a spectrum of diseases with various diabetic complications [39–41]. Several reports have shown a strong relation

Figure 2: Flow cytometry analysis of platelet activation showing percentage dual positive cells (CD61+, CD62P+). (a) Representation of the scattered plots of percentage platelet activation in the control (A, E), diabetes (B, F), AMS-treated diabetic (C, G), and aspirin-treated diabetic (D, H) groups after 3 and 10 weeks of study. Bar graph showing percentage platelet activation at the end of the 3rd week (b) and 10th week (c). All values are represented as mean ± SEM (N = 4-5). * \( p < 0.05 \) vs. the control; ** \( p < 0.01 \) vs. the control; *** \( p < 0.01 \) vs diabetes; and **** \( p < 0.001 \) vs diabetes; ns: nonsignificant.
between diabetes mellitus and premature cardiovascular events [4, 5]. The underlining mechanisms of cardiovascular complication in diabetes include several physiological and pathological changes in the heart, blood vessels, blood cells, and kidneys [42]. Previous scientific literature identified numerous risk factors i.e., hyperglycemia [43–45], dyslipidemia [46, 47], inflammation [48, 49], endothelial dysfunction, and oxidative stress [50, 51], which together can induce several complexities including cardiovascular complication in diabetes. Studies have also identified that alteration of normal platelet function as one of the major risk factors of diabetic complication and characterized by increased thromboxane synthesis [52], reduced membrane fluidity [53], and increased expression of activation-dependent adhesion molecules (e.g., GpIIb-IIIa and P-selectin) [54]. All of these changes make platelets more reactive and create a prothrombic environment in a diabetes patient [55, 56]. Nevertheless, the studies focusing on platelet dysfunc-

tion in type 1 diabetes (T1DM) and its modulation by pharmacological agents are limited. Recent literature says that among all the popular natural remedies, organosulfur compounds from garlic have shown a potential antidiabetic
and as well as antithrombotic effect in diabetic individual [17, 18, 22, 23, 57]. Previous research work also supported the role of garlic to attenuate cardiovascular complications in diabetes [18]. Allyl methyl sulfide (AMS) is one of the important sulfur compounds obtained from garlic, and studies showed that AMS is a major metabolite that is detected in the human breath and plasma [28]. Our previous study on AMS suggested that chronic administration of AMS is safe in control rats, where the body weight, food, and water intake along with the histopathology of major organs and serum biomarkers remained normal [30]. Further, the same study showed a beneficial effect of AMS on isoproterenol-induced cardiac fibrosis and dysregulated extracellular matrix (ECM) deposition in the myocardium [30]. Also, our recent finding showed a cardioprotective effect of AMS in pressure overload-induced cardiac hypertrophy and heart failure by ameliorating endogenous antioxidants and mitochondrial function [31]. Further research identified the therapeutic role of AMS on type 1 diabetes where different parameters like blood glucose, HbA1c, oxidative stress, inflammation, and insulinotropic activity were normalised after AMS treatment. All the above parameters remained normal in control rats after AMS administration [29, 58]. However, there is no study to find the effect of AMS on platelet activation. Therefore, in the current study, we determined the major platelet alterations in STZ-induced diabetic

**Figure 4:** Flow cytometry analysis of platelet aggregation after 10-week treatment. (a) Scatter plot of forward vs. side scatter of platelets from the control (A, E), diabetic (B, F), AMS-treated diabetic (C, G), and aspirin-treated diabetic (D, H) groups, representing percentage of platelet aggregation in the absence and presence of ADP. Bar graph represents percentage of platelet aggregation observed in absence (b) and presence (c) of ADP. All values are represented as mean ± SEM (N = 3). #p < 0.05 vs. diabetes; ns: nonsignificant.
AMS administered to STZ-induced diabetic rats showed a significant decrease in blood glucose level than aspirin. Our data is supporting the recent studies on AMS, where the activation of platelets was higher at a later stage (10 weeks) when compared to the initial stage (3 weeks) of diabetes. Moreover, we also observed the effect of AMS on platelet activation. Interestingly, we found a little reduction in platelet activation after initial treatment for 3 weeks with AMS but a significant decrease was found after 10 weeks of treatment. Here, our data suggest that long-term administration of AMS has a superior effect on reduction of platelet activation in diabetes.

Increased platelet activation results in increased platelet aggregation and has been detected in diabetes mellitus [37, 38]. This increased platelet aggregation is a result of increased systemic production of TxA2 by platelet [65], increased sensitivity of platelets agonist like ADP [66], and impaired production of platelet aggregation inhibitors PGI2 and NO [67, 68]. The previous finding has shown that the platelet of the diabetes patient was found to be 1.6-fold more sensitive to the ADP-induced aggregation than that of nondiabetes persons [69]. In the present study, we observed the aggregation of platelets (basal level) and its sensitivity to ADP stimuli in both the early (3rd week) and late (10th week) stages of diabetes. At early stages of the disease, there was no difference in the baseline aggregation property of platelets between the diabetes and control groups. However, in the presence of ADP, the diabetic platelets showed an increase in aggregation than the control group. The data suggests that the platelets from diabetic rats were highly sensitive and prone to thrombus formation. A decrease in baseline aggregation was observed in diabetic rats after AMS and aspirin treatment. The percentage of aggregation was also reduced when the platelets were activated by the addition of ADP in treatment groups. The study suggests that AMS has a beneficial effect in reducing the platelet sensitivity and aggregatory properties. Similar to platelet aggregation data in the 3rd week, we observed a decrease in baseline platelet aggregation in the 10th week after AMS and aspirin treatment. Interestingly, in the 10th week of diabetes, we did not observe any significant increase in ADP-induced platelet aggregation when compared to the control. Although we cannot explain the reason for not showing the sensitivity of platelets after ADP addition at week 10, it may be due to desensitization of P2Y1 and P2Y12 ADP receptors of platelets after the long-term interaction with endogenous ADP in chronic diabetes [70]. Further, the control group at 10th week showed higher basal platelet aggregation than the control group at 3rd week. This can be explained by the fact that age itself may enhance the platelet aggregation in the absence of diabetes [71]. After treatment with AMS for 10 weeks, we observed a decrease in ADP induced aggregation. The data overall indicated that inhibition was less at later stages of diabetes and may be due to the alteration of platelet structure and expression of major protein levels that resist the AMS’s beneficial effect.

Figure 5: Comparison of ROS levels among the control, diabetes, and treatment groups. All values are represented as mean ± SEM (N = 3-4). **p < 0.01 vs. the control; #p < 0.01 vs. diabetes; ns: nonsignificant.

Figure 6: Macrophage platelet interaction in the control, diabetes, and treatment groups. All values are represented as mean ± SEM (N = 3-5). **p < 0.01 vs. the control; ns: nonsignificant.

Rats and explored the antithrombotic effect of AMS, a bioactive derivative of garlic, mainly focusing on platelet activation.

In diabetes, controlling hyperglycemia is the primary goal to reduce complications of diabetes. Poor glycemic control affects platelet activation and vascular dysfunction in diabetes. A previous study reported that a low dose of aspirin reduces blood glucose levels in diabetic rats [59]. In our present study, AMS administration to rats reduced blood glucose levels. The result showed that AMS is more effective to reduce blood glucose level in diabetic rats than aspirin. Our data is supporting the recent studies on AMS, where AMS administered to STZ-induced diabetic rats showed a significant decrease in blood glucose level [58, 60].

Hyperglycemia along with other factors helps to aggregate the platelets in the presence of a small stimulus. Such platelets are referred to as hyperactivated platelets [61]. This hyperactivated platelet has distinct morphology and expresses P-selectin (CD69P) and GP IIb/IIIa receptor on the surface [62–64]. Supporting the previous data, our present study also observed an increase in platelet activation (CD62P levels) in type 1 diabetic rats when compared to nondiabetic rats. This activation of platelets was higher at a later stage (10 weeks) when compared to the initial stage (3 weeks) of diabetes. Moreover, we also observed the effect of AMS on platelet activation. Interestingly, we found a little reduction in platelet activation after initial treatment for 3 weeks with AMS but a significant decrease was found after 10 weeks of treatment. Here, our data suggest that long-term administration of AMS has a superior effect on reduction of platelet activation in diabetes.
Next, we correlated the platelet aggregation phenotype with intracellular ROS production. Increased ROS has been observed in activated platelets and activates the PKC pathway which led to platelet hyperactivity and aggregation [72]. Supporting the previous literature, our study also found increased ROS content in diabetic platelet when compared to the control. A recent study indicates that AMS administration improved the oxidative stress in STZ-induced hyperglycemic rats [58]. Based on their observation, we evaluated the endogenous ROS generation in platelets after AMS treatment and found an inhibitory effect of AMS on ROS production in platelets.

Increased ROS production can activate the platelets and help to participate in the signaling event of atherosclerosis in diabetes by forming aggregates with monocytes through P-selectin–PSGL-1 interactions [73]. Therefore, platelets play an important role in promoting inflammation in diabetes. The inflammatory condition created by PSGL-1-mediated monocyte activation leads to the synthesis and release of various chemokines, cytokines, and reactive oxygen species. Monocyte platelet interactions also have a role in the coagulation system by a surface expression of phosphatidylserine [74]. Previous literature suggested that increased platelet-monocyte aggregates are the indicator of in vivo platelet activation. These aggregates are responsible for the prothrombic stage and play a major role in the development of atherosclerosis in type 1 diabetes [75, 76]. Additionally, macrophage accumulation also plays a vital role in causing diabetic complications [77]. It was reported that a similar interaction between macrophages and platelets causes releases of chemokines and phagocytosis of platelets which further involve in atherothrombosis formation [78, 79].

In the present study, we observed platelet macrophage interactions to evaluate the platelet activation status as well as proinflammatory condition in type 1 diabetes. Here, in the present study, we observed an increase in macrophage and platelet interaction at late stages of diabetes compared to control, whereas after AMS treatment, diabetic rats showed less macrophage and platelet interactions compared to diabetes. The study suggests that AMS can reduce the macrophage and platelet interaction and can further inhibit pro-inflammatory condition which leads to vascular complication in diabetes.

5. Conclusion

In this study, we found that allyl methyl sulfide inhibits platelet activation and their aggregation in type 1 diabetes. It has also shown an inhibitory effect on increased platelet-macrophage interaction in type 1 diabetes. The increased platelet activation was associated with elevated levels of ROS. Further, our results showed a decrease in ROS levels in platelets after AMS treatment. The summary of the present study has been represented in Figure 7. Overall, this study provides a piece of strong evidence that treatment with AMS could prevent the phenotypic platelet changes seen in type 1 diabetes and may act as a potential therapeutic molecule for cardiovascular complications especially thrombosis in diabetes.

Data Availability

The data used to support the findings of this study are available from the corresponding author upon request.

Ethical Approval

Institutional Animal Ethics Committee (IAEC) Approval (NIPER/BT/2020/37) from National Institute of Pharmaceutical Education and Research (NIPER)-Guwahati to conduct the animal experiment was obtained.

Conflicts of Interest

The authors declare that there is no conflict of interest regarding the publication of this paper.
Authors’ Contributions

S.K.B., R.A, and N.M have designed the study. Animal handling and dosing were done by N.M. and S.K.U. Blood collection, platelet isolation, and sample preparation for flow analysis were performed by N.M., S.K.U., and V.T. Flow cytometry experiment design and analysis of platelet samples were done by both N.M and E.J. Statistical analysis and writing of the manuscript were done by S.K.B., R.A, M.J.A, and N.M.

Acknowledgments

The authors are grateful to the National Institute of Pharmaceutical Education and Research, Guwahati for providing the support and facility for this work. The authors are thankful to the Department of Biotechnology (DBT) and Indian Council of Medical Research (ICMR) for providing financial support of this work (Project no. BT/PR22881/BRB/10/1654/2018 and Project no. 3/1(2)(19)/OBS/2019-NCD-II, respectively). This study was also partly supported by National Institute of Pharmaceutical Education and Research, Guwahati core fund.

References

[1] IDF, “Diabetes Atlas 9th edition,” 2019 n.d., https://diabetesatlas.org/en/ ()
[2] C. O’Donnell, Diabetes, Contact Lens Practice, Elsevier, 2018.
[3] F. Paneni, J. A. Beckman, M. A. Creager, and F. Cosentino, “Diabetes and vascular disease: pathophysiology, clinical consequences, and medical therapy; part I,” European Heart Journal, vol. 34, no. 31, pp. 2436–2443, 2013.
[4] C. Alvarez, I. Lingvay, R. Koffarnus, and D. McGuire, “Cardiovascular risk in diabetes mellitus: complication of the disease or of antihyperglycemic medications,” Clinical Pharmacology and Therapeutics, vol. 98, pp. 145–161, 2015.
[5] E. Dal Canto, A. Ceriello, L. Rydén et al., “Diabetes as a cardiovascular risk factor: an overview of global trends of macro and micro vascular complications,” European Journal of Preventive Cardiology, vol. 26, 2_suppl, pp. 25–32, 2019.
[6] CVD Report.n.d. https://idf.org/our-activities/care-prevention/cardiovascular-disease/cvd-report/10-diabetes-and-cardiovascular-disease-report.html ()
[7] T. Behl, T. Velpandian, and A. Kotwani, “Role of altered coagulation-fibrinolytic system in the pathophysiology of diabetic retinopathy,” Vascular Pharmacology, vol. 92, pp. 1–5, 2017.
[8] P. Kubisz, L. Stančiaková, J. Staško, P. Galajda, and M. Mokáň, “Endothelial and platelet markers in diabetes mellitus type 2,” World Journal of Diabetes, vol. 6, pp. 423–431, 2015.
[9] J. A. Beckman, M. A. Creager, and P. Libby, “Diabetes and atherosclerosis: epidemiology, pathophysiology, and management,” JAMA, vol. 287, pp. 2570–2581, 2002.
[10] T. P. Fidler, A. Marti, K. Gerth et al., “Glucose metabolism is required for platelet hyperactivation in a murine model of type 1 diabetes,” Diabetologia, vol. 68, no. 5, pp. 932–938, 2019.
[11] B. Wang, T. Yee Aw, and K. Y. Stokes, “N-acetylcyesteine attenuates systemic platelet activation and cerebral vessel thrombosis in diabetes,” Redox Biology, vol. 14, pp. 218–228, 2018.
hyperglycemia mediated hepatic oxidative stress and inflammation in streptozotocin - induced experimental rats,” *Bio-
medicine & Pharmacotherapy*, vol. 107, pp. 292–302, 2018.

[30] S. A. Mohammed, B. Paramesha, Y. Kumar, U. Tariq, S. K. Arava, and S. K. Banerjee, “Allylmethylsulfide, a sulfur com-
 pound derived from garlic, attenuates isoproterenol-induced cardiac hypertrophy in rats,” *Oxidative Medicine and Cellular
 Longevity*, vol. 2020, pp. 15, 2020.

[31] S. A. Mohammed, B. Paramesha, H. Meghwani, M. P. Kumar Reddy, S. K. Arava, and S. K. Banerjee, “Allyl methyl sulfide
 preserved pressure overload-induced heart failure via modulation of mitochondrial function,” *Biomedicine & Pharcamo-
 therapy*, vol. 138, article 111316, 2021.

[32] I. M. de Cuyper, M. Meinders, E. van de Vijver et al., “A novel flow cytometry–based platelet aggregation assay,” *Blood*,
 vol. 121, no. 10, pp. e70–e80, 2013.

[33] M. Genin, F. Clement, A. Fattaccioli, M. Raes, and C. Michiels, “M1 and M2 macrophages derived from THP-1 cells dif-
 ferentially modulate the response of cancer cells to etoposide,” *BMC Cancer*, vol. 15, p. 577, 2015.

[34] M. Mehrpouri, D. Bashash, M. H. Mohammad, M. E. Ghey-
dari, E. S. Satlsar, and M. Hamidpouar, “Co-culture of platelets with monocytes induced M2 macrophage polarization and
 formation of foam cells: shedding light on the crucial role of platelets in monocyte differentiation,” *Turkish Journal of Hae-
matology*, vol. 36, pp. 97–105, 2019.

[35] T. G. Walsh, M. C. Berndt, N. Carrim, J. Cowman, D. Kenny, and P. Metharam, “The role of Nox1 and Nox2 in GPVI-
dependent platelet activation and thrombus formation,” *Redox Biology*, vol. 2, pp. 178–186, 2014.

[36] N. Carrim, J. F. Arthur, J. R. Hamilton et al., “Thrombin-
 induced reactive oxygen species generation in platelets: a novel role for protease-activated receptor 4 and GPIbα,” *Redox Biol-
 ogy*, vol. 6, pp. 640–647, 2015.

[37] N. H. Cho, D. J. Becker, D. Ellis, L. H. Kuller, A. L. Drash, and T. J. Orchard, “Spontaneous whole blood platelet aggregation,
 hematological variables and complications in insulin-dependent diabetes mellitus: the Pittsburgh Epidemiology of
 Diabetes Complications Study,” *Journal of Diabetes and its Complications*, vol. 6, pp. 12–18, 1992.

[38] C.-D. Agardh, E. Agardh, and B. Bauer, “Platelet aggregation
 in type I diabetics with and without proliferative retinopathy,” *Acta Ophthalmologica*, vol. 65, pp. 358–362, 2009.

[39] Z. T. Bloomgarden, “Diabetes complications,” *Diabetes Care*,
 vol. 27, pp. 1506–1514, 2004.

[40] M. J. Fowler, “Microvascular and macrovascular complica-
tions of diabetes,” *Clinical Diabetes*, vol. 26, pp. 77–82, 2008.

[41] B. Tripathi and A. Srivastava, “Diabetes mellitus: complications and therapies,” *Medical Science Monitor : Interna-
tional Medical Journal of Experimental and Clinical Research*, vol. 12, no. 7, pp. RA130–RA147, 2006.

[42] B. B. Dokken, “The pathophysiology of cardiovascular disease and diabetes: beyond blood pressure and lipids,” *Diabetes Spectrum: A Publication of the American Diabetes Association*, vol. 21, pp. 160–165, 2008.

[43] the DCCT/EDIC Research Group, I. Bebu, B. H. Braffett et al., “The relationship of blood glucose with cardiovascular disease
 is mediated over time by traditional risk factors in type 1 dia-
betes: the DCCT/EDIC study,” *Diabetologia*, vol. 60, no. 10, pp. 2084–2091, 2017.

[44] M. Lind, A.-M. Svensson, M. Kosiborod et al., “Glycemic con-
trol and excess mortality in type 1 diabetes,” *The New England Journal of Medicine*, vol. 371, no. 21, pp. 1972–1982, 2014.

[45] G. R. Sousa, D. Pober, A. Galdersi et al., “Glycemic control, cardiac autoimmunity, and long-term risk of cardiovascular
disease in type 1 Diabetes Mellitus,” *Circulation*, vol. 139, no. 6, pp. 730–743, 2019.

[46] H. M. Mona, S. A. Sahar, S. M. Hend, and A.-W. A. Nanees,
“Dyslipidemia in type 1 diabetes mellitus: relation to diabetes
duration, glycemic control, body habitus, dietary intake and other epidemiological risk factors,” *Egyptian Pediatric Associa-
tion Gazette*, vol. 63, pp. 63–68, 2015.

[47] S. Rahma, J. A. Rashid, and A. H. A. Farage, “The significance of lipid abnormalities in children with insulin-dependant dia-
betes mellitus,” *Iraqi Postgraduate Medical Journal*, vol. 6, 2006.

[48] M. Lechleitner, T. Koch, M. Herold, A. Dzien, and F. Hopichler, “Tumour necrosis factor-alpha plasma level in patients
with type 1 diabetes mellitus and its association with glycaemic control and cardiovascular risk factors,” *Journal of Internal
Medicine*, vol. 248, pp. 67–76, 2000.

[49] S. Tsalamandris, A. S. Antonopoulos, E. Oikonomou et al., “The role of inflammation in diabetes: current concepts and
future perspectives,” *Eur Cardiol*, vol. 14, no. 1, pp. 50–59, 2019.

[50] P. Martin-Gallán, A. Carrascosa, M. Gussinyé, and C. Domínguez, “Biomarkers of diabetes-associated oxidative stress and
antioxidant status in young diabetic patients with or without subclinical complications,” *Free Radical Biology and Medicine*,
vol. 34, no. 12, pp. 1563–1574, 2003.

[51] G. Marra, P. Cotroneo, D. Pitocco et al., “Early increase of ox-
idative stress and reduced antioxidant defenses in patients
with uncomplicated type 1 diabetes: a case for gender difference,” *
Diabetes Care*, vol. 25, no. 2, pp. 370–375, 2002.

[52] P. Alessandri, J. McRae, S. Feman, and G. A. FitzGerald,
“Thromboxane biosynthesis and platelet function in type 1 dia-
betes mellitus,” *New England Journal of Medicine*, vol. 319, no. 4, pp. 208–212, 1988.

[53] P. D. Winocour, C. Watala, and R. L. Michelson, Ed., pp. 469–
503, Academic Press, 2019.

[54] E. Block, B. Bechand, S. Gundala et al., “Fluorinated analogs of
organosulfur compounds from garlic (Allium sativum): Syn-
thesis, Chemistry and Anti-Angiogenesis and Antithrombotic
Studies,” *Chemistry and Anti-Angiogenesis and Antithrombotic
Studies. Molecules*, vol. 22, no. 12, p. 2081, 2017.
[58] K. Sujithra, S. Srinivasan, D. Indumathi, and V. Vinothkumar, "Allyl methyl sulfide, a garlic active component mitigates hyperglycemia by restoration of circulatory antioxidant status and attenuating glycoprotein components in streptozotocin-induced experimental rats," *Toxicology Mechanisms and Methods*, vol. 29, pp. 165–176, 2019.

[59] L. M. Coe, J. D. Denison, and L. R. McCabe, "Low dose aspirin therapy decreases blood glucose levels but does not prevent type 1 diabetes-induced bone loss," *Cellular Physiology and Biochemistry*, vol. 28, pp. 923–932, 2011.

[60] S. K. Banerjee, M. Maulik, S. C. Manchanda, A. K. Dinda, T. K. Das, and S. K. Maulik, "Garlic-induced alteration in rat liver and kidney morphology and associated changes in endogenous antioxidant status," *Food and Chemical Toxicology*, vol. 39, pp. 793–797, 2001.

[61] D. J. Schneider, "Factors contributing to increased platelet reactivity in people with diabetes," *Diabetes Care*, vol. 32, pp. 525–527, 2009.

[62] V. Venkatesh, R. Kumar, D. K. Varma, P. Bhatia, J. Yadav, and D. Dayal, "Changes in platelet morphology indices in relation to duration of disease and glycemic control in children with type 1 diabetes mellitus," *Journal of Diabetes and its Complications*, vol. 32, pp. 833–838, 2018.

[63] A. M. Zahran, O. El-Badawy, I. L. Mohamad, D. M. Tamer, S. M. Abdel-Aziz, and K. I. Elsayh, "Platelet activation and platelet-leukocyte aggregates in type 1 diabetes mellitus," *Clinical and Applied Thrombosis/Hemostasis*, vol. 24, pp. 2305–2395, 2018.

[64] I. Tarnow, A. D. Michelson, M. R. Barnard et al., "Nephropathy in type 1 diabetes is associated with increased circulating activated platelets and platelet hyperreactivity," *Platelets*, vol. 20, no. 7, pp. 513–519, 2009.

[65] P. V. Halushka, R. C. Rogers, C. B. Loadholt, and J. A. Colwell, "Increased platelet thromboxane synthesis in diabetes mellitus," *The Journal of Laboratory and Clinical Medicine*, vol. 97, no. 1, pp. 87–96, 1981.

[66] H. Heath, W. D. Bhigden, J. V. Canever et al., "Platelet adhesiveness and aggregation in relation to diabetic retinopathy," *Diabetologia*, vol. 7, no. 5, pp. 308–315, 1971.

[67] A. Schäfer and J. Bauersachs, "Endothelial dysfunction, impaired endogenous platelet inhibition and platelet activation in diabetes and atherosclerosis," *Current Vascular Pharmacology*, vol. 6, pp. 52–60, 2008.

[68] G. Anfossi, E. M. Mularoni, S. Burzacca et al., "Platelet resistance to nitrates in obesity and obese NIDDM, and normal platelet sensitivity to both insulin and nitrates in lean NIDDM," *Diabetes Care*, vol. 21, no. 1, pp. 121–126, 1998.

[69] I. I. Chirkov, I. A. Tyshchiuk, I. S. Severina, and L. K. Starosels'tseva, "ADP-induced aggregation of human platelets in diabetes mellitus," *Voprosy Meditsinskoi Khimii*, vol. 36, no. 4, pp. 20–22, 1990.

[70] R. Mahmoodian, M. Salimian, M. Hamidpour, A. A. Khadem-Maboudi, and A. Gharehbaghi, "The effect of mild agonist stimulation on the platelet reactivity in patients with type 2 diabetes mellitus," *BMC Endocrine Disorders*, vol. 19, p. 62, 2019.

[71] D. Kasjanovová and V. Baláz, "Age-related changes in human platelet function in vitro," *Mechanisms of Ageing and Development*, vol. 37, pp. 175–182, 1986.

[72] P. Ferroni, S. Basili, A. Falco, and G. Davi, "Platelet activation in type 2 diabetes mellitus," *Journal of Thrombosis and Hemostasis*, vol. 2, pp. 1282–1291, 2004.

[73] Z. Patko, A. Császár, G. Acsády, I. Ory, E. Takacs, and J. Furesz, "Elevation of monocyte-platelet aggregates is an early marker of type 2 diabetes," *Interventional Medicine & Applied Science*, vol. 4, pp. 181–185, 2012.

[74] I. del Conde, C. N. Shrimpton, P. Thiagarajan, and J. A. López, "Tissue-factor-bearing microvesicles arise from lipid rafts and fuse with activated platelets to initiate coagulation," *Blood*, vol. 106, no. 5, pp. 1604–1611, 2005.

[75] S.-H. Yun, E.-H. Sim, R.-Y. Goh, J.-I. Park, and J.-Y. Han, "Platelet activation: the mechanisms and potential biomarkers," *BioMed Research International*, vol. 2016, Article ID 567253, 5 pages, 2016.

[76] S. A. Harding, A. J. Sommerfield, J. Sarma et al., "Increased CD40 ligand and platelet-monocyte aggregates in patients with type 1 diabetes mellitus," *Atherosclerosis*, vol. 176, no. 2, pp. 321–325, 2004.

[77] G. H. Tesch, "Role of macrophages in complications of type 2 diabetes," *Clinical and Experimental Pharmacology and Physiology*, vol. 34, pp. 1016–1019, 2007.

[78] B. A. Badlou, Y. P. Wu, W. M. Smid, and J.-W. N. Akkerman, "Platelet binding and phagocytosis by macrophages," *Transfusión*, vol. 46, pp. 1432–1443, 2006.

[79] K. Daub, H. Langer, P. Seizer et al., "Platelets induce differentiation of human CD34+ progenitor cells into foam cells and endothelial cells," *The FASEB Journal*, vol. 20, no. 14, pp. 2559–2561, 2006.